Abstract
Objectives To estimate the prevalence of unpaid caregiving during the coronavirus disease 2019 (COVID-19) pandemic, and to identify factors associated with adverse mental health symptoms, substance use, and suicidal ideation in this population, which provides critical support in health care systems by providing care to older adults and those with chronic conditions.
Methods In June 2020, Internet-based surveys with questions about demographics, caregiving responsibilities, and mental health were administered to US adults aged ≥18 years. Demographic quota sampling and survey weighting to improve cross-sectional sample representativeness of age, gender, and race/ethnicity. Prevalence ratios for adverse mental health symptoms were estimated using multivariable Poisson regressions.
Results Of 9,896 eligible invited adults, 5,412 (54.7%) completed surveys; 5,011 (92.6%) respondents met screening criteria and were analysed, including 1,362 (27.2%) caregivers. Caregivers had higher prevalences of adverse mental health symptoms than non-caregivers, including anxiety or depressive disorder symptoms (57.6% vs 21.5%, respectively, p<0.0001) having recently seriously considered suicide (33.4% vs 3.7%, p<0.0001). Symptoms were more common among caregivers who were young vs older adults (e.g., aged 18–24 vs ≥65 years, aPR 2.75, 95% CI 1.95–3.88, p<0.0001), Hispanic or Latino vs non-Hispanic White (1.14, 1.04–1.25, p=0.0044), living with vs without disabilities (1.18, 1.10–1.26, p<0.0001), and with moderate and high vs low Caregiver Intensity Index scores (2.31, 1.65–3.23; 2.81, 2.00–3.94; both p<0.0001). Suicidal ideation was more prevalent among non-Hispanic Black vs non-Hispanic White caregivers (1.48, 1.15–1.90, p=0.0022).
Conclusions Caregivers, who accounted for one in four US adult respondents in this nationally representative sample, more commonly reported adverse mental health symptoms than non-caregivers. Increased visibility of and access to mental health care resources are urgently needed to address mental health challenges of caregiving.
Competing Interest Statement
All authors report grants from Whoop, Inc., which supported in part administration of the survey in June 2020, and other support from ARCHANGELS, which permitted the investigators to use the proprietary ARCHANGELS Caregiver Intensity Index for this study without cost. Mr Czeisler reports grants from Australian-American Fulbright Commission administered through a 2020 Fulbright Future Scholarship funded by The Kinghorn Foundation, and personal fees from Vanda Pharmaceuticals, outside the submitted work. Ms Drane is co-founder of and employed by ARCHANGELS and receives salary and has equity. Ms Drane reports grants from Ralph C Wilson Junior Foundation; personal fees from Prudential Financial Services and Walmart; and other from RAND Health, Rosalynn Carter Institute for Caregivers, United States of Care - Entrepreneurs Council, Open Notes, Executive Council for Division of Sleep Medicine - Harvard Medical School, Massachusetts Technology Collaborative, C-TAC, EndWell, Beth Israel Deaconess Medical Center, MassChallenge Health Tech, Boston Children's Hospital, Health Evolution, Edenbridge Health, WHOOP, and HPT Development/Drane Associates, outside the submitted work. Ms Stephens Winnay reports a grant from Ralph C Wilson Junior Foundation (RCWJF), outside the submitted work. In addition, Ms Drane and Ms Winnay have a patent ARCHANGELS - Planned pending on the ARCHANGELS Caregiver Intensity Index, and a patent ARCHANGELS CII - Trademark pending on the ARCHANGELS Caregiver Intensity Index. Ms Capodilupo is employed by WHOOP, Inc., from which she receives salary and is a company shareholder, and is on the board of advisors at ARCHANGELS, and is a company shareholder. Dr Czeisler reports institutional education and research support from Cephalon, Inc. and from Philips Respironics Inc.; institutional grants from National Institute of Occupational Safety and Health R01-OH-011773; personal fees from and equity interest in Vanda Pharmaceuticals Inc; personal fees from Teva Pharmaceuticals Industries Ltd, Teva Pharma Australia, outside the submitted work. In addition, Dr Czeisler has a patent for the Actiwatch-2 and Actiwatch-Spectrum devices, with royalties paid from Philips Respironics Inc. Dr Czeisler's interests were reviewed and managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict of interest policies. Dr Czeisler served as a voluntary board member for the Institute for Experimental Psychiatry Research Foundation, Inc. Dr Shantha Rajaratnam reports grants from Turner Institute for Brain and Mental Health, Monash University; grants and personal fees from Cooperative Research Centre for Alertness, Safety and Productivity; grants and institutional consulting fees from Vanda Pharmaceuticals, and Teva Pharmaceuticals; and institutional consulting fees from BHP Billiton, Circadian Therapeutics, and Herbert Smith Freehills, outside the submitted work. Dr Mark Howard reports a grant from the Institute for Breathing and Sleep, Austin Health. No other potential competing interests were declared.
Funding Statement
This study was supported in part by the Institute for Breathing and Sleep, Austin Health; the Turner Institute for Brain and Mental Health, Monash University; by a gift to the Harvard Medical School and Brigham and Women's Hospital from Philips Respironics, Inc; by a gift to Brigham and Women's Hospital from Alexandra Drane, the CEO of ARCHANGELS; and by a contract from Whoop Inc. to Monash University. MÉC was supported by a 2020 Fulbright Future Scholarship funded by The Kinghorn Foundation through the Australian-American Fulbright Commission. CAC was supported in part by the National Institute of Occupational Safety and Health R01-OH-010300, and by an endowed professorship at Harvard Medical School funded by Cephalon, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Monash University Human Research Ethics Committee reviewed and approved the study protocol (ID #24036).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are presented in the report and available from the corresponding author upon reasonable request.
